- Abstract Number: 2144
JAK Inhibition Re-balances Gene Expression Profile of Circulating Immune Cells in Patients with Psoriatic Arthritis
- Abstract Number: 0559
JAK Inhibitor Withdrawal Causes a Transient Proinflammatory Signaling Cascade in Minor Salivary Gland Mesenchymal Stromal Cells
- Abstract Number: 2216
JAK Inhibitors and Risk of Cancer
- Abstract Number: 0653
JAK Inhibitors Counteract Cellular Toxicity of Hydroxychloroquine in Vitro
- Abstract Number: 2015
JAK Selectivity Did Not Affect to the Incidence of Malignancies in the Real-World Setting: Data from a Multicenter Observational Study in Japan
- Abstract Number: 0464
JAKINIB in Refractory Giant Cell Arteritis. National Multicenter Study of 15 Cases and Literature Review
- Abstract Number: 0135
Janus Kinase Inhibitors in Severe and Refractory Inflammatory Ocular Pathology. Cases Reports and Literature Review
- Abstract Number: 1285
Joint Injection Workflow in Rheumatology – an Opportunity to Improve Efficiency and Physician Satisfaction
- Abstract Number: 1382
Juvenile Eosinophilic Fasciitis: A Single-Center Cohort
- Abstract Number: 1371
Juvenile Onset SLE in India-Data from a Multi-institutional Inception (INSPIRE) Cohort of Systemic Lupus Erythematosus
- Abstract Number: 0515
Juvenile Systemic Sclerosis Treatment Practices in an International Cohort and Comparison to Recent SHARE Consensus Guidelines
ACR Convergence 2022
November 10-14, 2022. Philadelphia, PA.